Memorial Sloan Kettering Cancer Center

Cornell University

Richard John O'Reilly

Aisha Nasreen Hasan

Ekaterina Doubrovina

Susan Elizabeth Prockop

Guenther Koehne

Annamalai Selvakumar

Szilard Kiss

Bo Dupont

Xiao-Rong Liu

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15Rα complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15Rα complexes are also provided.

Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

Methods of selecting T cell line and donor thereof for adoptive cellular therapy

Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof comprise administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Methods of treating CMV retinitis by T cell therapy

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (Tcells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.

Generation and use in adoptive immunotherapy of stem cell-like memory T cells

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.

Immunogenic WT-1 peptides and methods of use thereof

The invention relates to methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.

Methods of treating Epstein-Barr virus-associated lymphoproliferative disorders by T cell therapy

Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Growing community of inventors

Roxbury, CT, United States of America

Richard John O'Reilly